Primary Erythromelalgia

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Xenon Pharmaceuticals
2 programs
2
XPF-001Phase 1/21 trial
XPF-002Phase 1/21 trial
Active Trials
NCT01090622Completed4Est. Sep 2010
NCT01486446Completed8Est. May 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Xenon PharmaceuticalsXPF-002
Xenon PharmaceuticalsXPF-001

Clinical Trials (2)

Total enrollment: 12 patients across 2 trials

NCT01486446Xenon PharmaceuticalsXPF-002

Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

Start: Dec 2011Est. completion: May 20128 patients
Phase 1/2Completed
NCT01090622Xenon PharmaceuticalsXPF-001

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Start: Apr 2010Est. completion: Sep 20104 patients
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space